Literature DB >> 24629617

Assessment of the reliability of standard automated perimetry in regions of glaucomatous damage.

Stuart K Gardiner1, William H Swanson2, Deborah Goren3, Steven L Mansberger3, Shaban Demirel3.   

Abstract

PURPOSE: Visual field testing uses high-contrast stimuli in areas of severe visual field loss. However, retinal ganglion cells saturate with high-contrast stimuli, suggesting that the probability of detecting perimetric stimuli may not increase indefinitely as contrast increases. Driven by this concept, this study examines the lower limit of perimetric sensitivity for reliable testing by standard automated perimetry.
DESIGN: Evaluation of a diagnostic test. PARTICIPANTS: A total of 34 participants with moderate to severe glaucoma; mean deviation at their last clinic visit averaged -10.90 dB (range, -20.94 to -3.38 dB). A total of 75 of the 136 locations tested had a perimetric sensitivity of ≤ 19 dB.
METHODS: Frequency-of-seeing curves were constructed at 4 nonadjacent visual field locations by the Method of Constant Stimuli (MOCS), using 35 stimulus presentations at each of 7 contrasts. Locations were chosen a priori and included at least 2 with glaucomatous damage but a sensitivity of ≥ 6 dB. Cumulative Gaussian curves were fit to the data, first assuming a 5% false-negative rate and subsequently allowing the asymptotic maximum response probability to be a free parameter. MAIN OUTCOME MEASURES: The strength of the relation (R(2)) between perimetric sensitivity (mean of last 2 clinic visits) and MOCS sensitivity (from the experiment) for all locations with perimetric sensitivity within ± 4 dB of each selected value, at 0.5 dB intervals.
RESULTS: Bins centered at sensitivities ≥ 19 dB always had R(2) >0.1. All bins centered at sensitivities ≤ 15 dB had R(2) <0.1, an indication that sensitivities are unreliable. No consistent conclusions could be drawn between 15 and 19 dB. At 57 of the 81 locations with perimetric sensitivity <19 dB, including 49 of the 63 locations ≤ 15 dB, the fitted asymptotic maximum response probability was <80%, consistent with the hypothesis of response saturation. At 29 of these locations the asymptotic maximum was <50%, and so contrast sensitivity (50% response rate) is undefined.
CONCLUSIONS: Clinical visual field testing may be unreliable when visual field locations have sensitivity below approximately 15 to 19 dB because of a reduction in the asymptotic maximum response probability. Researchers and clinicians may have difficulty detecting worsening sensitivity in these visual field locations, and this difficulty may occur commonly in patients with glaucoma with moderate to severe glaucomatous visual field loss.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24629617      PMCID: PMC4082764          DOI: 10.1016/j.ophtha.2014.01.020

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  45 in total

1.  Test-retest variability in structural and functional parameters of glaucoma damage in the glaucoma imaging longitudinal study.

Authors:  Henry D Jampel; Susan Vitale; Yulan Ding; Harry Quigley; David Friedman; Nathan Congdon; Ran Zeimer
Journal:  J Glaucoma       Date:  2006-04       Impact factor: 2.503

2.  The effective dynamic ranges of standard automated perimetry sizes III and V and motion and matrix perimetry.

Authors:  Michael Wall; Kimberly R Woodward; Carrie K Doyle; Gideon Zamba
Journal:  Arch Ophthalmol       Date:  2010-05

3.  Responses of primate retinal ganglion cells to perimetric stimuli.

Authors:  William H Swanson; Hao Sun; Barry B Lee; Dingcai Cao
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-09       Impact factor: 4.799

Review 4.  A framework for comparing structural and functional measures of glaucomatous damage.

Authors:  Donald C Hood; Randy H Kardon
Journal:  Prog Retin Eye Res       Date:  2007-08-21       Impact factor: 21.198

5.  Repeatability of automated perimetry: a comparison between standard automated perimetry with stimulus size III and V, matrix, and motion perimetry.

Authors:  Michael Wall; Kimberly R Woodward; Carrie K Doyle; Paul H Artes
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

6.  Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study.

Authors:  Stuart K Gardiner; Shaban Demirel; Carlos Gustavo De Moraes; Jeffrey M Liebmann; George A Cioffi; Robert Ritch; Mae O Gordon; Michael A Kass
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-15       Impact factor: 4.799

7.  Linking structure and function in glaucoma.

Authors:  R S Harwerth; J L Wheat; M J Fredette; D R Anderson
Journal:  Prog Retin Eye Res       Date:  2010-03-11       Impact factor: 21.198

8.  A two-stage neural spiking model of visual contrast detection in perimetry.

Authors:  S K Gardiner; W H Swanson; S Demirel; A M McKendrick; A Turpin; C A Johnson
Journal:  Vision Res       Date:  2008-07-21       Impact factor: 1.886

9.  Development and evaluation of a contrast sensitivity perimetry test for patients with glaucoma.

Authors:  Aliya Hot; Mitchell W Dul; William H Swanson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-31       Impact factor: 4.799

Review 10.  Practical recommendations for measuring rates of visual field change in glaucoma.

Authors:  B C Chauhan; D F Garway-Heath; F J Goñi; L Rossetti; B Bengtsson; A C Viswanathan; A Heijl
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

View more
  76 in total

1.  What rates of glaucoma progression are clinically significant?

Authors:  Luke J Saunders; Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill
Journal:  Expert Rev Ophthalmol       Date:  2016-05-13

2.  Localized Changes in Retinal Nerve Fiber Layer Thickness as a Predictor of Localized Functional Change in Glaucoma.

Authors:  Stuart K Gardiner; Brad Fortune; Shaban Demirel
Journal:  Am J Ophthalmol       Date:  2016-08-01       Impact factor: 5.258

3.  Reducing variability in visual field assessment for glaucoma through filtering that combines structural and functional information.

Authors:  Lisha Deng; Shaban Demirel; Stuart K Gardiner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-26       Impact factor: 4.799

4.  Effect of a variability-adjusted algorithm on the efficiency of perimetric testing.

Authors:  Stuart K Gardiner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-06       Impact factor: 4.799

5.  Measuring Rates of Visual Field Progression in Linear Versus Nonlinear Scales: Implications for Understanding the Relationship Between Baseline Damage and Target Rates of Glaucoma Progression.

Authors:  Kevin Liebmann; Carlos Gustavo De Moraes; Jeffrey M Liebmann
Journal:  J Glaucoma       Date:  2017-08       Impact factor: 2.503

Review 6.  Functional assessment of glaucoma: Uncovering progression.

Authors:  Rongrong Hu; Lyne Racette; Kelly S Chen; Chris A Johnson
Journal:  Surv Ophthalmol       Date:  2020-04-26       Impact factor: 6.048

7.  OCT Circle Scans Can Be Used to Study Many Eyes with Advanced Glaucoma.

Authors:  Seung H Lee; Devon B Joiner; Emmanouil Tsamis; Rashmi Rajshekhar; Eleanor Kim; C Gustavo De Moraes; Robert Ritch; Donald C Hood
Journal:  Ophthalmol Glaucoma       Date:  2019-02-12

8.  Detecting Change Using Standard Global Perimetric Indices in Glaucoma.

Authors:  Stuart K Gardiner; Shaban Demirel
Journal:  Am J Ophthalmol       Date:  2017-01-25       Impact factor: 5.258

9.  Comparison between broadband and monochromatic photopic negative response in full-field electroretinogram in controls and subjects with primary open-angle glaucoma.

Authors:  Aniruddha Banerjee; Mona Khurana; Ramya Sachidanandam; Parveen Sen
Journal:  Doc Ophthalmol       Date:  2019-01-12       Impact factor: 2.379

10.  Differences in the Relation Between Perimetric Sensitivity and Variability Between Locations Across the Visual Field.

Authors:  Stuart K Gardiner
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-07-02       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.